[Molybdocene dichloride as an antitumor agent (author's transl)].

The antitumor activity of molybdocene dichloride is tested against Ehrlich ascites tumor in CF1 mice. The application of 75 of 100 mg/kg 24 h after transplantation achieves 100% tumor inhibition until day 30. Following the d0 and d1 metallocene dichlorides of titanium and vanadium, molybdocene dichloride is the first analogous d2 system revealing similar antineoplastic properties.